MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

CRISPR Therapeutics AG

Fermé

SecteurSoins de santé

32.77 -4.07

Résumé

Variation du prix de l'action

24h

Actuel

Min

32.17

Max

34.17

Chiffres clés

By Trading Economics

Revenu

49M

-37M

Ventes

34M

35M

BPA

-0.44

Marge bénéficiaire

-106.603

Employés

393

EBITDA

46M

-60M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+109.36% upside

Dividendes

By Dow Jones

Prochains Résultats

6 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

3.2B

Ouverture précédente

36.84

Clôture précédente

32.77

Sentiment de l'Actualité

By Acuity

54%

46%

323 / 386 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

CRISPR Therapeutics AG Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

26 sept. 2024, 16:08 UTC

Résultats
Acquisitions, Fusions, Rachats

Pfizer's Strategy Looks Shakier After Sickle-Cell Disappointment -- Barrons.com

26 sept. 2024, 14:20 UTC

Acquisitions, Fusions, Rachats

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. -- IBD

11 avr. 2024, 14:46 UTC

Acquisitions, Fusions, Rachats

Vertex Pharmaceuticals Seeks a Second Act With $4.9B Deal to Buy Alpine Immune -- Barrons.com

Comparaison

Variation de prix

CRISPR Therapeutics AG prévision

Objectif de Prix

By TipRanks

109.36% hausse

Prévisions sur 12 Mois

Moyen 71.58 USD  109.36%

Haut 120 USD

Bas 32 USD

Basé sur 20 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

20 ratings

12

Achat

7

Maintien

1

Vente

Score Technique

By Trading Central

32.96 / 36.93Support & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Strong Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

323 / 386Classement par Soins de santé

Sentiment de l'Actualité

Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.